Usiwoma Abugo, MD
Ophthalmic Plastic and Reconstructive Surgery · Timonium, MDNPI 1447510953
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.4%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Amgen accounts for 60.3% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $4,645 and has fallen 53.7% since, to $2,152 in 2025.
Across 62 payments — averaging $189.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$7K
- Tarsus Pharmaceuticals, Inc.$2K
- Johnson & Johnson Surgical Vision, Inc.$2K
- AbbVie$486
- Johnson & Johnson Vision Care, Inc.$320
- Galderma Laboratories, L.p.$115
- plus $556 from 11 others
What the payments were for
- Consulting fees$2,67223%
- Speaking & faculty fees$6,26353%
- Food & beverage$2,79424%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 26 | $7,078 |
| Tarsus Pharmaceuticals, Inc. | 5 | $1,630 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $1,544 |
| AbbVie(2 entities) | 8 | $486 |
| Johnson & Johnson Vision Care, Inc. | 2 | $320 |
| Galderma Laboratories, L.p. | 2 | $115 |
| Mallinckrodt Enterprises LLC | 1 | $114 |
| Eyevance Pharmaceuticals LLC | 1 | $96 |
| Sun Pharmaceutical Industries Inc. | 2 | $71 |
| Glaukos Corporation | 1 | $60 |
| Mallinckrodt Hospital Products Inc. | 2 | $52 |
| Bausch & Lomb Americas Inc. | 2 | $44 |
| Dompe US, Inc. | 1 | $35 |
| Alcon | 2 | $28 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $25 |
| Novartis | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEPEZZA$6,493
- Tecnis Simplicity$1,642
- AMO PHACO NEEDLE$187
- ACTHAR$114
- LUMIGAN$113
How this compares
Too few ophthalmic plastic and reconstructive surgery providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 36 | $30,776 |
| Loteprednol Etabonate | 22 | $2,614 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 122 | $1,451 |
| Difluprednate | 11 | $830 |
| ErythromycinErythromycin Base | 13 | $162 |
| Prednisone | 37 | $78 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 24 | $76 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $44 | $30,77636 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $25 | $2,61422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few ophthalmic plastic and reconstructive surgery providers in Marylandon file to place this against a meaningful peer group, so we don't.
Other ophthalmic plastic and reconstructive surgery in Timonium
- Orin ZwickAnnapolis$2K
- Sajeev KathuriaLutherville Timonium$2K
- Rosalie BairBethesda$1K
- Kevin PermanBethesda$1K
- Jonathan ButtramBethesda$1K
- Elba PachecoSeverna Park$199
- Brian LeeEllicott City$140
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.